Cargando…
Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial
BACKGROUND AND AIM: Adrenomedullin is a bioactive peptide with many pleiotropic effects, including mucosal healing and immunomodulation. Adrenomedullin has shown beneficial effects in rodent models of inflammatory bowel disease and, more importantly, in clinical trials including patients with ulcera...
Autores principales: | Kita, Toshihiro, Ashizuka, Shinya, Takeda, Teruyuki, Matsumoto, Takayuki, Ohmiya, Naoki, Nakase, Hiroshi, Motoya, Satoshi, Ohi, Hidehisa, Mitsuyama, Keiichi, Hisamatsu, Tadakazu, Kanmura, Shuji, Kato, Naoya, Ishihara, Shunji, Nakamura, Masanao, Moriyama, Tomohiko, Saruta, Masayuki, Nozaki, Ryoichi, Yamamoto, Shojiro, Inatsu, Haruhiko, Watanabe, Koji, Kitamura, Kazuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796011/ https://www.ncbi.nlm.nih.gov/pubmed/35840351 http://dx.doi.org/10.1111/jgh.15945 |
Ejemplares similares
-
Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2020) -
Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease
por: Ashizuka, Shinya, et al.
Publicado: (2021) -
Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series
por: Ashizuka, Shinya, et al.
Publicado: (2015) -
Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
por: Ashizuka, Shinya, et al.
Publicado: (2019) -
Effect of a concomitant elemental diet with maintenance anti‐tumor necrosis factor‐α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study
por: Hirai, Fumihito, et al.
Publicado: (2018)